{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:49:31Z","timestamp":1785527371192,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08159-3","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:17:22Z","timestamp":1785291442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4069-7494","authenticated-orcid":false,"given":"Shiza","family":"Zainab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Zaheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamna Raheel","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zayd","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amena","family":"Khatoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Zakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshal","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalsoom","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atifa","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair ul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahira","family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"8159_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.blo.0000132404.30139.f2","volume":"425","author":"JT Lin","year":"2004","unstructured":"Lin JT, Lane JM (2004) Osteoporosis: a review. Clin Orthop Relat Res 425:126\u2013134. https:\/\/doi.org\/10.1097\/01.blo.0000132404.30139.f2","journal-title":"Clin Orthop Relat Res"},{"issue":"929","key":"8159_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/pmj.79.929.133","volume":"79","author":"C Christodoulou","year":"2003","unstructured":"Christodoulou C, Cooper C (2003) What is osteoporosis? Postgrad Med J 79(929):133\u2013138. https:\/\/doi.org\/10.1136\/pmj.79.929.133","journal-title":"Postgrad Med J"},{"key":"8159_CR3","doi-asserted-by":"publisher","unstructured":"Kamel HK (2006) Postmenopausal Osteoporosis. J Manag Care Pharm 12(6 Supp A):S4\u20139. https:\/\/doi.org\/10.18553\/jmcp.2006.12.s6-a.1","DOI":"10.18553\/jmcp.2006.12.s6-a.1"},{"issue":"1","key":"8159_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s1098-3597(06)80052-x","volume":"8","author":"JP Levine","year":"2006","unstructured":"Levine JP (2006) Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone 8(1):40\u201353. https:\/\/doi.org\/10.1016\/s1098-3597(06)80052-x","journal-title":"Clin Cornerstone"},{"key":"8159_CR5","doi-asserted-by":"publisher","unstructured":"Aapro M, Hadji P, Santini D et al (2025) Biosimilars in osteoporosis treatment: focus on denosumab. Expert Opin Biol Ther:1\u20132. https:\/\/doi.org\/10.1080\/14712598.2024.2389100","DOI":"10.1080\/14712598.2024.2389100"},{"issue":"1","key":"8159_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.japh.2021.08.020","volume":"62","author":"RN Okoro","year":"2022","unstructured":"Okoro RN, Hedima EW, Aguiyi-Ikeanyi CN (2022) Knowledge, attitudes, and practices of pharmacists toward biosimilar medicines in Nigeria. J Am Pharm Assoc 62(1):79\u201385. https:\/\/doi.org\/10.1016\/j.japh.2021.08.020","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"8159_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/19420862.2016.1267087","volume":"9","author":"M Beck","year":"2017","unstructured":"Beck M, Michel B, Rybarczyk-Vigouret MC et al (2017) Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines. MAbs 9(2):384\u2013391. https:\/\/doi.org\/10.1080\/19420862.2016.1267087","journal-title":"MAbs"},{"issue":"1","key":"8159_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/ijp.ijp_789_20","volume":"53","author":"I Singh","year":"2021","unstructured":"Singh I, Jose V, Patel R et al (2021) Denosumab biosimilar in postmenopausal osteoporotic women: a randomized, assessor-blind, active-controlled clinical trial. Indian J Pharmacol 53(1):6\u201312. https:\/\/doi.org\/10.4103\/ijp.ijp_789_20","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"8159_CR9","doi-asserted-by":"publisher","first-page":"e1951","DOI":"10.1210\/clinem\/dgae022","volume":"110","author":"B Langdahl","year":"2025","unstructured":"Langdahl B, Chung YS, Plebanski R et al (2025) Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis. J Clin Endocrinol Metab 110(6):e1951\u2013e1958. https:\/\/doi.org\/10.1210\/clinem\/dgae022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8159_CR10","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.5005\/japi-11001-1444","volume":"73","author":"T Paul","year":"2025","unstructured":"Paul T, Garg B, Kapoor N et al (2025) A prospective, active-controlled, randomized, double-blind, multicenter, phase III study to compare the safety and efficacy of biosimilar denosumab vs reference denosumab. J Assoc Physicians India 73(1):e8\u201313. https:\/\/doi.org\/10.5005\/japi-11001-1444","journal-title":"J Assoc Physicians India"},{"issue":"3","key":"8159_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jbmr\/zjae004","volume":"39","author":"S Jeka","year":"2024","unstructured":"Jeka S, Dokoupilov\u00e1 E, Kivitz A et al (2024) Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. J Bone Miner Res 39(3):202\u2013210. https:\/\/doi.org\/10.1093\/jbmr\/zjae004","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8159_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS et al (2012) Bench to bedside: elucidation of the OPG\u2013RANK\u2013RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401\u2013419. https:\/\/doi.org\/10.1038\/nrd3705","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"8159_CR13","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1080\/13696998.2025.2584885","volume":"28","author":"J Flanigan","year":"2025","unstructured":"Flanigan J, Chaplin S, van Stiphout J, Schauf M, Tindal M, Gundlach A, Li E, Lyman GH (2025) A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population. J Med Econ 28(1):2027\u20132038","journal-title":"J Med Econ"},{"issue":"2","key":"8159_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","volume":"16","author":"PJ Bekker","year":"2001","unstructured":"Bekker PJ, Holloway D, Nakanishi A et al (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16(2):348\u2013360. https:\/\/doi.org\/10.1359\/jbmr.2001.16.2.348","journal-title":"J Bone Miner Res"},{"issue":"2","key":"8159_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass. Bone 43(2):222\u2013229. https:\/\/doi.org\/10.1016\/j.bone.2008.04.007","journal-title":"Bone"},{"issue":"8","key":"8159_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821\u2013831. https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"N Engl J Med"},{"issue":"4","key":"8159_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3349\/ymj.2016.57.4.905","volume":"57","author":"JM Koh","year":"2016","unstructured":"Koh JM, Chung DJ, Chung YS et al (2016) Assessment of denosumab in Korean postmenopausal women with osteoporosis. Yonsei Med J 57(4):905\u2013911. https:\/\/doi.org\/10.3349\/ymj.2016.57.4.905","journal-title":"Yonsei Med J"},{"issue":"6","key":"8159_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00223-023-01074-x","volume":"112","author":"MR Moshi","year":"2023","unstructured":"Moshi MR, Nicolopoulos K, Stringer D et al (2023) The clinical effectiveness of denosumab (Prolia\u00ae) for the treatment of osteoporosis in postmenopausal women. Calcif Tissue Int 112(6):631\u2013646. https:\/\/doi.org\/10.1007\/s00223-023-01074-x","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"8159_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis. Lancet Diabetes Endocrinol 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"8159_CR20","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00198-015-3196-x","volume":"26","author":"S Ferrari","year":"2015","unstructured":"Ferrari S, Adachi JD, Lippuner K et al (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment. Osteoporos Int 26(12):2763\u20132771. https:\/\/doi.org\/10.1007\/s00198-015-3196-x","journal-title":"Osteoporos Int"},{"key":"8159_CR21","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.2147\/DDDT.S270829","volume":"14","author":"KL Pang","year":"2020","unstructured":"Pang KL, Low NY, Chin KY (2020) A review on the role of denosumab in fracture prevention. Drug Des Devel Ther 14:4029\u20134051. https:\/\/doi.org\/10.2147\/DDDT.S270829","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"8159_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-011-1673-x","volume":"23","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Matsumoto T, Sugimoto T et al (2012) Dose\u2013response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women. Osteoporos Int 23(3):1131\u20131140. https:\/\/doi.org\/10.1007\/s00198-011-1673-x","journal-title":"Osteoporos Int"},{"issue":"8","key":"8159_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"2","key":"8159_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41401-022-00962-6","volume":"44","author":"H Zhang","year":"2023","unstructured":"Zhang H, Gu JM, Chao AJ et al (2023) A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206. Acta Pharmacol Sin 44(2):446\u2013453. https:\/\/doi.org\/10.1038\/s41401-022-00962-6","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"8159_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26(3):530\u2013537. https:\/\/doi.org\/10.1002\/jbmr.251","journal-title":"J Bone Miner Res"},{"issue":"12","key":"8159_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70089","volume":"17","author":"N Li","year":"2024","unstructured":"Li N, Chu N, Zhu L et al (2024) Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab. Clin Transl Sci 17(12):e70089. https:\/\/doi.org\/10.1111\/cts.70089","journal-title":"Clin Transl Sci"},{"key":"8159_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00223-023-01078-z","volume":"112","author":"MR Moshi","year":"2023","unstructured":"Moshi MR, Nicolopoulos K, Stringer D et al (2023) The clinical effectiveness of denosumab (Prolia\u00ae) for the treatment of osteoporosis in postmenopausal women, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis. Calcif Tissue Int 112:631\u2013646. https:\/\/doi.org\/10.1007\/s00223-023-01078-z","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"8159_CR28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00198-014-2956-4","volume":"26","author":"T Sugimoto","year":"2015","unstructured":"Sugimoto T, Matsumoto T, Hosoi T et al (2015) Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis. Osteoporos Int 26(2):765\u2013774. https:\/\/doi.org\/10.1007\/s00198-014-2956-4","journal-title":"Osteoporos Int"},{"key":"8159_CR29","unstructured":"FDA (2019) Immunogenicity Testing of Therapeutic Protein Products. https:\/\/www.fda.gov\/media\/119788\/download. Accessed 28 Dec 2025"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08159-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:11:53Z","timestamp":1785521513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":29,"alternative-id":["8159"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08159-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}